Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01702896 · ClinicalTrials.gov registry record · Phase 2
Interleukin-2 in Metastatic Melanoma
A Phase 2 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01702896: Clinical Trial Phase 2 study, sponsored by Western Regional Medical Center.
NCT01702896 is a Phase 2 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01702896, a Phase 2 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
Primary Outcome
Radiographic studies to evaluate for response were done after every 2 cycles (6 weeks) until disease progression or death from any cause up to 2 years. Standard RECIST response criteria were utilized. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = 100
Interventions
- DRUG Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Why NCT01702896 stopped before completion
NCT01702896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Interleukin-2 is the first listed.
NCT01702896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01702896 about?
NCT01702896 is a clinical study titled "Interleukin-2 in Metastatic Melanoma". To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
What is the current status of trial NCT01702896?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2012-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01702896?
The interventions under investigation include: Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT01702896?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01702896's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia